Galera Therapeutics, Inc. (NASDAQ: GRTX) - quick internal read: the company has effectively pivoted after a failed FDA resubmission path for avasopasem, completed the acquisition of Nova Pharmaceuticals (tilarginine/pan‑NOS program), sharply reduced headcount and is operating with minimal staff w...